

Tuesday 10 September, 2024 (half day – morning)

Demystifying the Science Behind Targeted Treatments and Immunotherapies for Melanoma

9.00 Registration

9.30 Biology and genetics of melanoma

- Cell of origin and mechanisms of development
- Key genetic mutations in malignant melanoma
- Growth factor receptor signalling pathways and the normal functions of B-Raf and MEK
- Melanoma and the immune system a dynamic relationship

10.15 Short break

10.25 Immunotherapy with checkpoint inhibitors

- T cells the key to immunotherapy
- Checkpoint inhibitor mechanism of action
- Why checkpoint inhibitors often work against melanoma
- Licensed checkpoint inhibitors and a summary of trials

11.00 Coffee break

11.20 B-Raf and MEK inhibitors

- Inhibitors of growth factor signalling pathways
- Mechanism of action of B-Raf inhibitors
- The problem of cancer evolution
- Resistance mechanisms to B-Raf/MEK inhibitors
- B-Raf/MEK inhibitor combinations the same or different?
- Which first: immunotherapy or targeted therapy?

11.50 Short break

12.00 Other forms of immunotherapy

- Newer checkpoint inhibitors: LAG3 antibodies
- Oncolytic virus: T-VEC
- Tumour-infiltrating lymphocyte (TIL) therapy
- Tebentafusp for uveal melanoma
- mRNA vaccines

12.30 Close